Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in Primary Immune Thrombocytopenia
NCT05995054Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2023; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05995054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995054.